2025-09-11 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the provided data. The report is written in English, starts with key figures, and adds analysis.

**Teladoc Health Inc. (TDOC) Analysis**

**Company Overview:** Teladoc Health Inc. is a telehealth and virtual healthcare company providing a range of services, including virtual doctor visits and expert medical opinions.

**1. Performance vs. S&P 500 (VOO)**

*   **TDOC Cumulative Return:** -63.14%
*   **VOO Cumulative Return:** 39.61%
*   **Absolute Divergence:** -102.75% (-63.14 - 39.61)
*   **Relative Divergence:** 0.3 (Min: -162.2, Max: 460.3)

**Analysis:** TDOC has significantly underperformed the S&P 500.  The cumulative return difference is substantial. The relative divergence of 0.3 suggests that TDOC's performance is near the lowest end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2015-2017  | 76.0%   | 60.6% | 76.0%  | 1.0  | 5.9    |
| 2016-2018  | 128.0%  | 59.3% | 128.0% | 1.0  | 8.4    |
| 2017-2019  | 176.0%  | 59.3% | 176.0% | 1.0  | 14.2   |
| 2018-2020  | 237.0%  | 64.0% | 237.0% | 1.0  | 33.9   |
| 2019-2021  | -83.0%  | 64.0% | -84.0% | -0.0 | 15.6   |
| 2020-2022  | -295.0% | 81.3% | -284.0% | -0.0 | 4.0    |
| 2021-2023  | -488.0% | 81.3% | -498.0% | 0.0  | 3.7    |
| 2022-2024  | -111.0% | 81.3% | -141.0% | 0.0  | 1.5    |
| 2023-2025  | -34.0%  | 75.5% | -80.0%  | 0.0  | 1.3    |

**Analysis:**  The table shows a dramatic decline in performance in recent years.  CAGR (Compound Annual Growth Rate) has shifted from very high positive values to significantly negative values. Maximum Drawdown (MDD) remains high, indicating substantial risk. Alpha is consistently negative in recent periods, suggesting underperformance relative to a benchmark. Beta has decreased to near zero, indicating a lack of correlation with the market (S&P 500). Market Cap is in sharp decline.

**2. Recent Price Action**

*   **Current Price:** 7.80
*   **Last Market Data:** Price: 7.49, Previous Close: 7.8, Change: -3.97%
*   **5-Day Moving Average:** 7.77
*   **20-Day Moving Average:** 7.57
*   **60-Day Moving Average:** 7.72

**Analysis:** The stock experienced a decrease of -3.97%. The 5-day moving average is slightly above the 20-day moving average, which in turn is slightly below the 60-day moving average.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3261 (Low Risk)
*   **RSI:** 63.77 (Approaching overbought territory)
*   **PPO:** 0.5475
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **20-Day Relative Divergence Change:** 0.2 (Positive - Short-term increase)
*   **Expected Return:** -9841.3% (Long-term, relative to S&P 500)

**Analysis:**  The MRI indicates Low risk, but the negative expected return is extremely concerning. RSI is approaching overbought. The positive change in relative divergence suggests a recent short-term upward movement, but it doesn't negate the overall poor performance.

**4. Recent News & Significant Events**

*   **[2025-09-10]** Assessing the Latest Valuation After Recent Share Price Momentum (Simply Wall St.)
*   **[2025-09-10]** Institutional owners hold 73% of the company (Simply Wall St.)
*   **[2025-09-05]** 2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
*   **[2025-09-02]** 1 Cash-Producing Stock on Our Buy List and 2 We Find Risky (StockStory)
*   **[2025-08-28]** Up 4.6% Since Last Earnings Report? (Zacks)
*   **[2025-08-28]** Telehealth and Telemedicine Company Evaluation Report 2025 (GlobeNewswire)

**Analysis:**  The news is mixed. While some articles discuss valuation and institutional ownership, others are negative, including being listed as a stock to avoid.

**4-2. Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.64 (~Hold)
*   **Target Price (avg/high/low):** 9.12 / 12.00 / 7.00

**Analysis:** The analyst consensus is "Hold," with an average target price suggesting a modest upside. However, the low target price is near the current price. The lack of recent rating changes suggests analysts are not making drastic revisions.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-07-30 | -0.19 | 0.63 B$   |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2025-07-30 | -4.92 | 0.64 B$   |

**Analysis:** Earnings per share (EPS) has been negative for all reported periods. While revenue has remained relatively stable, the persistent losses are a concern.

**6. Financial Information**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.63B    | 69.85%        |
| 2025-03-31   | $0.63B    | 68.73%        |
| 2024-12-31   | $0.64B    | 70.50%        |
| 2024-09-30   | $0.64B    | 71.94%        |
| 2024-06-30   | $0.64B    | 70.73%        |

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $1.42B    | -2.30%   |
| 2025-03-31   | $1.43B    | -6.52%   |
| 2024-12-31   | $1.49B    | -3.25%   |
| 2024-09-30   | $1.51B    | -2.21%   |
| 2024-06-30   | $1.50B    | -55.77%  |

**Analysis:**  Revenue is relatively consistent, and profit margins are high. However, Return on Equity (ROE) is negative, indicating the company is not generating profits from its equity.

**7. Overall Assessment**

Teladoc Health (TDOC) exhibits several concerning indicators:

*   **Significant underperformance compared to the S&P 500.**
*   **Negative CAGR, high MDD, and negative Alpha over recent periods.**
*   **Negative EPS and ROE, despite stable revenue and high profit margins.**
*   **Mixed news sentiment.**
*   **Extremely negative expected return.**

While the analyst consensus is "Hold," the overall picture suggests significant risk. The extremely negative expected return warrants serious caution. The high profit margins, consistent revenues, and relatively low MRI are the few positive points.
